Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 20/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14675561 | 0.99 | FOLH1 (0.62) | FOLH1 | |
| SCHEMBL20879602 | 0.95 | FOLH1 (0.59) | FOLH1 | |
| SCHEMBL19403116 | 0.88 | FOLH1 (0.73) | FOLH1 | |
| SCHEMBL17119753 | 0.87 | FOLH1 (0.75) | FOLH1 | |
| SCHEMBL25575645 | 0.87 | FOLH1 (0.75) | FOLH1 | |
| SCHEMBL11930724 | 0.86 | FOLH1 (0.67) | FOLH1 | |
| SCHEMBL25574479 | 0.86 | FOLH1 (0.71) | FOLH1 | |
| SCHEMBL18655464 | 0.86 | FOLH1 (0.70) | FOLH1 | |
| SCHEMBL23790343 | 0.86 | FOLH1 (0.67) | FOLH1 | |
| SCHEMBL16781668 | 0.85 | FOLH1 (0.73) | FOLH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3505192-A1 | RADIOLABELED PROSTATE SPECIFIC MEMBRANE ANTIGEN INHIBITORS | Molecular Insight Pharmaceuticals, Inc. (US) | 2019-07-03 | — | — | EP | disclosed |
| EP-3505192-A1 | RADIOLABELED PROSTATE SPECIFIC MEMBRANE ANTIGEN INHIBITORS | Molecular Insight Pharmaceuticals, Inc. (US) | 2019-07-03 | — | — | EP | disclosed |
| EP-2739316-B1 | RADIOLABELED PROSTATE SPECIFIC MEMBRANE ANTIGEN INHIBITORS | MOLECULAR INSIGHT PHARM INC (US) | 2019-04-10 | — | — | EP | disclosed |
| US-9388144-B2 | Radiolabeled prostate specific membrane antigen inhibitors | MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) | 2016-07-12 | — | — | US | disclosed |
| US-9388144-B2 | Radiolabeled prostate specific membrane antigen inhibitors | MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) | 2016-07-12 | — | — | US | disclosed |
| US-20150078998-A1 | RADIOLABELED PROSTATE SPECIFIC MEMBRANE ANTIGEN INHIBITORS | MOLECULAR INSIGHT PHARMACEUTICALS (US) | 2015-03-19 | — | — | US | disclosed |
| US-20150078998-A1 | RADIOLABELED PROSTATE SPECIFIC MEMBRANE ANTIGEN INHIBITORS | MOLECULAR INSIGHT PHARMACEUTICALS (US) | 2015-03-19 | — | — | US | disclosed |
| US-8926944-B2 | Radiolabeled prostate specific membrane antigen inhibitors | MOLECULAR INSIGHT PHARMACEUTICALS (US) | 2015-01-06 | — | — | US | disclosed |
| US-8926944-B2 | Radiolabeled prostate specific membrane antigen inhibitors | MOLECULAR INSIGHT PHARMACEUTICALS (US) | 2015-01-06 | — | — | US | disclosed |
| WO-2013022797-A1 | RADIOLABELED PROSTATE SPECIFIC MEMBRANE ANTIGEN INHIBITORS | MOLECULAR INSIGHT PHARMACEUTICALS (US) | 2013-02-14 | — | — | WO | disclosed |
| US-20130034494-A1 | RADIOLABELED PROSTATE SPECIFIC MEMBRANE ANTIGEN INHIBITORS | MOLECULAR INSIGHT PHARMACEUTICALS | 2013-02-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130034494-A1 | RADIOLABELED PROSTATE SPECIFIC MEMBRANE ANTIGEN INHIBITORS | KLK3, FOLH1, PSMA1 | FOLH1 2/4885 |
| US-20150078998-A1 | RADIOLABELED PROSTATE SPECIFIC MEMBRANE ANTIGEN INHIBITORS | KLK3, FOLH1, PSMA2 | FOLH1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.